Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Accell 100 is a demineralized bone matrix (DBM) putty used as a bone graft substitute in orthopedic, spinal, and reconstructive surgeries. Developed by Integra LifeSciences, it is composed of 100% human-derived DBM without the addition of extrinsic carriers like glycerol or sodium hyaluronate. The product utilizes the proprietary Accell Bone Matrix (ABM) process, which provides a high concentration of naturally occurring Bone Morphogenetic Proteins (BMPs) and other growth factors. Its mechanism of action involves both osteoconduction, where the matrix serves as a scaffold for new bone growth, and osteoinduction, where the BMPs recruit and stimulate mesenchymal stem cells to differentiate into bone-forming osteoblasts. It is primarily indicated for filling bone voids or gaps that are not intrinsic to the stability of the bony structure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Accell 100.